FDA Approves Amgen's XGEVA(R) (denosumab) For The Treatment Of Giant Cell Tumor Of Bone

XGEVA Becomes First FDA-Approved Treatment for This Rare Disease THOUSAND OAKS, Calif., June 13, 2013 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indicati... Biopharmaceuticals, Oncology, FDAAmgen, XGEVA, denosumab, giant cell tumor of bone
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news